Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib

NCT ID: NCT02040480

Last Updated: 2017-11-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-05
• Study Completion Date: 2014-04-04

Brief Summary

This study is being conducted to measure the relative bioavailability of the original gelatin capsule formulation and a new formulation, immediate release (IR) tablet of Afuresertib (GSK2110183). The study will be composed of Screening, Treatment, and Follow-up Periods. A subject's total time involved in the study will be approximately 9 weeks. The study will enroll approximately 18 healthy volunteers.

Conditions

Cancer

Keywords

bioavailability; food effect; formulation; GSK2110183; afuresertib; AKT inhibitor

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sequence 1

Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC

Group Type: EXPERIMENTAL

GSK2110183 Gelatin Capsule

Intervention Type: DRUG

White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

GSK2110183 IR Tablet

Intervention Type: DRUG

White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Sequence 2

Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB

Group Type: EXPERIMENTAL

GSK2110183 Gelatin Capsule

Intervention Type: DRUG

White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

GSK2110183 IR Tablet

Intervention Type: DRUG

White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Sequence 3

Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC

Group Type: EXPERIMENTAL

GSK2110183 Gelatin Capsule

Intervention Type: DRUG

White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

GSK2110183 IR Tablet

Intervention Type: DRUG

White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Sequence 4

Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA

Group Type: EXPERIMENTAL

GSK2110183 Gelatin Capsule

Intervention Type: DRUG

White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

GSK2110183 IR Tablet

Intervention Type: DRUG

White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Sequence 5

Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB

Group Type: EXPERIMENTAL

GSK2110183 Gelatin Capsule

Intervention Type: DRUG

White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

GSK2110183 IR Tablet

Intervention Type: DRUG

White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Sequence 6

Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA

Group Type: EXPERIMENTAL

GSK2110183 Gelatin Capsule

Intervention Type: DRUG

White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

GSK2110183 IR Tablet

Intervention Type: DRUG

White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Interventions

GSK2110183 Gelatin Capsule

White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration

Intervention Type: DRUG

GSK2110183 IR Tablet

White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Provided signed written informed consent
• Healthy Male or female between 18 and 40 years of age inclusive, at the time the informed consent is obtained.
• Body weight >=50 kilograms (kg) and body mass index (BMI) of >=18 and <= 32 kg/meter square (m^2).
• A female subject is eligible to participate if she is of (A) Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy or postmenopausal defined as 12 months of spontaneous amenorrhea (B) Child-bearing potential with negative pregnancy test as determined by serum human chorionic gonadotropin (hCG) test at Screening and prior to dosing, AND: agrees to use one of the acceptable contraception methods
• Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods.
• Alanine aminotransferase, alkaline phosphatase and bilirubin <=1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
• Based on single or averaged QT interval corrected (QTc) values of triplicate ECGs obtained over a brief recording period: QTcB <450 millisecond (msec); or QTcB <480 msec in subjects with Bundle Branch Block.
• Able to swallow and retain orally administered study treatment and does not have any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels.

Exclusion Criteria

• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
• History of gastroesophageal reflux disease, dyspepsia, peptic ulcer disease, gastrointestinal (GI) bleeding, GI surgery that could affect motility.
• History of atrial arrhythmias
• History of regular alcohol consumption within 6 months of the study defined as:

An average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 10 grams (g) of alcohol: 270 mL of full strength beer (4.8%), 375 mL of mid strength beer (3.5%), 470 mL of light beer (2.7%), 250 mL pre-mix full strength spirit (5%), 100mL of wine (13.5%) and 30 mL of spirit (40%).

• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates their participation
• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of Screening.
• Smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
• A positive drug/alcohol screen at Screening or upon check-in to the clinic on Day -1 of each Dosing Period.
• A positive test for human immuno virus (HIV) antibody.
• Pregnant females as determined by positive serum hCG test at Screening or prior to dosing.
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
• Lactating females.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
• Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures.
• Any prohibited medications or recent consumption of citrus products.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Randwick, New South Wales, Australia

Countries

Australia

Other Identifiers

201039

Identifier Type: -

Identifier Source: org_study_id